CME vs. Morningstar: Which Financial Stock Is a Better Buy in 2026?
CME Group (CME) and Morningstar (MORN) are compared as financial infrastructure stocks. CME reported $6.5B revenue, $4B net income, and a 62% net margin in 2025. Morningstar reported $2.4B revenue, $374.2M net income, and a 15.3% net margin. Both face competitive and operational risks.
How this was made

The 30-second read
Why it matters
The article offers no new information beyond what was already disclosed in the companies' annual reports, limiting trading relevance.
Market read
A recap of existing financial data; low immediate trading relevance.
What to watch
Potential future regulatory changes for CME and AI‑risk for Morningstar are mentioned but not quantified.
Background
The piece is a comparative analysis of CME Group and Morningstar using their FY2025 financial results and valuation metrics.
Ticker impact
Article recaps CME Group's FY2025 revenue, net income and free cash flow figures from its annual report.
Limited impact; price likely unchanged.
Numbers are already public; article provides no fresh information.
Article summarizes Morningstar's FY2025 revenue, net income and free cash flow from its annual filing.
Limited impact; price likely unchanged.
Data were disclosed earlier; article adds no new insight.
Market effects
Provides a side‑by‑side view of financial‑services infrastructure firms, but no new sector shift.
U.S. financial‑services sector only; no broader regional effect.
Limited; comparison of two U.S. listed companies.
Counterpoint
Without fresh data, any trade based on this comparison is speculative.
Key entities
- companyCME Group
Global derivatives exchange operator.
- companyMorningstar
Investment research and data provider.


